Syndax Pharmaceuticals' excess liquidity indicates a cautiou...

Syndax Pharmaceuticals' excess liquidity indicates a cautious approach to debt, but its lack of significant operating revenue and EBIT loss over the last year are worrying. The company's balance sheet appears liquid, but the absence of regular free cash flow generation is concerning.